Login to Your Account

CRT, Merck Serono Ink Deal for Drugs to Block WNT Signal

By Nuala Moran
Staff Writer

Tuesday, August 6, 2013
LONDON – Cancer Research Technology Ltd. (CRT) agreed to its third licensing deal in six weeks, signing up Merck Serono SA to take forward compounds that block the WNT cell-signaling pathway.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription